Last reviewed · How we verify

NCT04370119: SeCo

Screening for COVID-19 and Monitoring of Serological Responses to SARS-CoV-2 in Healthcare Workers

Completed Last updated 20 November 2025
What this trial tests

trial testing Nasal swab in SARS-CoV-2 in 1,092 participants. Completed in 27 April 2025.

Timeline
27 April 2020
Primary endpoint
23 April 2021
27 April 2025

Quick facts

Lead sponsorUniversity Medicine Greifswald
StatusCompleted
Study typeOBSERVATIONAL
Enrollment1,092
Start date27 April 2020
Primary completion23 April 2021
Estimated completion27 April 2025
Sites1 location across Germany

Drugs / interventions tested

Conditions studied

Sponsor

University Medicine Greifswald

Who can join

18 and older, any sex, with SARS-CoV-2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main objectives of this study are 1) to establish the prevalence of SARS-CoV-2 in asymptomatic healthcare workers (HCWs) in an early phase of community spread as well as 2) to monitor the future spread of the disease by assessing serological responses to SARS-CoV-2 in symptomatic and asymptomatic HCWs over time and 3) to improve the assessment of the immune response and its protective effect as well as the assessment of infectivity of affected HCWs and 4) to evaluate the value and significance of antibody formation and serological antibody tests and 5) to be able to evaluate possible future preventive and / or therapeutic approaches against SARS-CoV-2, e.g. to assess vaccination effects

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

  1. A flow cytometric assay to detect platelet-activating antibodies in VITT after ChAdOx1 nCov-19 vaccination.
    Handtke S, Wolff M, Zaninetti C, Wesche J, et al · · 2021 · cited 54× · PMID 33945605 · DOI 10.1182/blood.2021012064
  2. The role of routine SARS-CoV-2 screening of healthcare-workers in acute care hospitals in 2020: a systematic review and meta-analysis.
    Jabs JM, Schwabe A, Wollkopf AD, Gebel B, et al · · 2022 · cited 14× · PMID 35780088 · DOI 10.1186/s12879-022-07554-5
  3. Platelet-activating histone/antihistone IgG complexes in anti-PF4-negative thrombosis and thrombocytopenia syndrome.
    Esefeld M, Handtke S, Kaiser R, Nicolai L, et al · · 2025 · cited 5× · PMID 40179418 · DOI 10.1182/bloodadvances.2024015076

Verify or expand the search:

Other trials of Nasal swab

Trials testing the same drug.

Other recruiting trials for SARS-CoV-2

Currently open trials in the same condition.

Other University Medicine Greifswald trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04370119.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing